Human Papillomavirus (HPV): Types, Spread, Clearance & Cancer Risk

• HPV is a family of 200+ viruses; only about 15 high-risk types can cause cancer, and types 16 and 18 alone cause around 70% of cervical cancers.
• Your body clears roughly 70% of HPV infections within a year and about 90% within two years. A positive test is not a cancer diagnosis.
• Cervical cancer takes 10-20 years to develop from persistent infection, leaving a wide window for screening to catch pre-cancer early.
• Vaccination works best before sexual debut (ages 9-14). India's indigenous Cervavac (about Rs 2000/dose) has made it far more affordable than imported Gardasil 9.
• Vaccination does not replace screening. Vaccinated women still need age-appropriate Pap or HPV tests.
• HPV cannot be dated or traced to one partner, so it is never proof of infidelity. Stigma, not the virus, is the biggest barrier to prevention in India.

Human papillomavirus is not a single virus but a family of more than 200 closely related DNA viruses that infect epithelial cells, the cells lining your skin and mucous membranes. About 40 of these types infect the genital tract, and they fall into two broad groups by their cancer-causing potential. Low-risk types, mainly HPV 6 and 11, cause genital warts but do not cause cancer. High-risk (oncogenic) types, including 16, 18, 31, 33, 45, 52, and 58, can produce persistent infection that slowly drives the cellular changes leading to cervical, anal, vulvar, vaginal, and oropharyngeal cancers.

According to the International Agency for Research on Cancer (IARC), HPV 16 and 18 together cause about 70 percent of cervical cancers worldwide, with the remaining ~30 percent spread across the other high-risk types. In India, HPV 16 alone accounts for roughly 60 percent of cervical cancers, an unusually heavy contribution that has shaped which vaccines are prioritised here.

The virus enters through tiny breaks in the skin or mucosa during sexual contact, then targets the basal cells of the epithelium and hijacks their replication cycle. In most people the immune system recognises and clears it within one to two years. This is why an HPV diagnosis is not a permanent label: a test that is positive today may well be negative a year from now, and that is the expected outcome, not a surprise.

It is also important to know that HPV is not a marker of recent infidelity. Because the virus can stay dormant for years, a positive test today cannot tell you when or from whom infection was acquired. The American College of Obstetricians and Gynecologists (ACOG) states plainly that HPV detection cannot date the infection or identify the source partner. This matters because shame and blame have historically driven women away from the screening that prevents cervical cancer.

HPV is not only a cervical issue, either. Oncogenic types also drive a rising share of head and neck cancers, particularly of the tonsils and base of the tongue, and anal cancer rates are higher in men who have sex with men and in women living with HIV. The cervix stays the focus because cervical cancer is uniquely preventable through screening, but HPV is best understood as a multi-site virus.

The biology that turns infection into cancer is worth a moment. High-risk types make two proteins, E6 and E7, that switch off two human tumour-suppressor proteins, p53 and Rb. Normally p53 triggers repair or cell death when DNA is damaged, while Rb keeps cells from dividing at the wrong time. With both disabled, damaged cells keep dividing, and over years this produces the increasingly abnormal cells that show up as low- and high-grade dysplasia. Because the process is so slow, screening every three to five years is enough to catch it in time.

HPV spreads mainly through direct skin-to-skin and mucosa-to-mucosa contact, most often during vaginal, anal, or oral sex. This is a key difference from HIV or hepatitis B, which need an exchange of blood or specific fluids. Because HPV lives in skin cells, any sustained genital contact can transmit it, even without penetration, ejaculation, or visible lesions. This is also why condoms reduce HPV risk substantially but not completely, since they don't cover all the skin involved. ACOG summarises evidence that consistent condom use cuts HPV transmission by roughly 70 percent, making them worthwhile but not absolute protection.

Infection is extremely common at the start of sexual activity. Population data summarised by the WHO show that new HPV infection peaks within the first few years after sexual debut, often in the late teens and early twenties. Many young people acquire and clear several types in this window without ever knowing. Cumulative lifetime exposure approaches 80 percent in sexually active populations, which is why vaccination works best before sexual debut, ideally at ages 9 to 14, when the immune response is strongest and exposure has not yet happened.

Non-sexual transmission is uncommon but not impossible. A baby can rarely acquire HPV during vaginal delivery, occasionally causing recurrent respiratory papillomatosis (fewer than 4 cases per 100,000 births globally). Transmission via objects like towels is hypothesised but not considered meaningful in adults. Importantly, HPV is not spread by toilet seats, swimming pools, sharing utensils, or casual touch, and clearing up that confusion is part of good care.

Partner patterns often drive distress. HPV is so common that within a long-term monogamous relationship both partners are very likely to share the same types, even if only one has been tested. The American Society for Reproductive Medicine (ASRM) notes there is no useful routine HPV test for men, because the virus is harder to detect on male anatomy and the result would not change management. Partners cannot easily be 'screened' or 'cleared.' The more useful focus is each person managing their own surveillance and vaccination.

There is also a biological asymmetry. The cervical transformation zone is unusually susceptible to HPV and to persistent infection, which is one reason cervical cancer is the most common HPV-related cancer even though men and women are roughly equally exposed. In adolescents and young women this zone is especially large, which is why early exposure carries somewhat higher long-term risk, not for any moral reason but because of more cumulative exposure time and more vulnerable tissue. For context on how the infection sits among other STIs, see our overview of sexually transmitted infections and their types.

One of the most important things to understand about HPV is that the body usually wins. Roughly 70 percent of new infections clear within one year, and about 90 percent within two years. This is true for both low-risk and high-risk types. Clearance does not always mean the virus is gone completely; sometimes it persists at undetectable levels and may or may not reactivate. But functionally, a cleared infection no longer drives cellular change and no longer puts you at active risk from that episode. This is a hopeful fact that deserves far more emphasis than it usually gets.

The minority of infections that fail to clear within two years are the ones that matter for cancer risk. Persistent infection with a high-risk type, especially HPV 16, is the single strongest predictor of progression to high-grade cervical dysplasia and eventually cancer. The mechanism is the E6 and E7 oncoproteins described earlier, which let damaged cells keep dividing instead of being repaired or destroyed. The clinical takeaway: a single positive test does not equal disease. What matters is whether the same high-risk type is still present a year or two later, which is also why screening every three to five years is safe for low-risk results.

Several factors influence whether infection persists. The most consistent ones, per ACOG, include current smoking (nicotine and tar metabolites concentrate in cervical mucus and suppress local immunity), immunosuppression (HIV, transplant, long-term steroids), high parity (more than five term pregnancies), prolonged combined oral contraceptive use beyond about five years, and possibly deficiencies in folate, vitamin A, and vitamin D. General immune health from sleep and nutrition matters too, though it is harder to quantify.

For Indian women specifically, the high rate of late-stage cervical cancer reflects the fact that without screening, persistent infection has decades to progress unnoticed. ICMR data show nearly 70 percent of cervical cancers in India are diagnosed at stage II or later, when treatment is far harder and survival drops sharply. This is not because HPV is more aggressive here; it is because screening has not historically reached most women. The newer push for HPV testing as a primary screen, backed by tertiary centres like AIIMS Delhi, PGI Chandigarh, and Tata Memorial Mumbai, is designed to catch persistent infection earlier.

Reinfection versus reactivation often confuses patients. After clearance, the same person can be reinfected with the same type later, especially with a new partner, because natural immunity is incomplete. This is also why vaccination after clearance still helps: the vaccine produces a stronger, more durable antibody response than natural infection, protecting against reinfection.

The HPV vaccine is one of the most studied vaccines in history, with over a decade of post-licensure data confirming its safety and effectiveness. Three imported vaccines have been used in India: Cervarix (bivalent, types 16 and 18), Gardasil 4 (quadrivalent, adding 6 and 11 for warts), and Gardasil 9 (adding 31, 33, 45, 52, and 58). In 2022 the Serum Institute of India launched Cervavac, an indigenous quadrivalent vaccine against types 6, 11, 16, and 18 at around Rs 2000 per dose, versus roughly Rs 10,500 per dose for Gardasil 9. This price drop is genuinely transformative for population access and has been welcomed by FOGSI. You can read more in our dedicated guide to the HPV vaccine in India.

The schedule depends on age at the first dose. Girls and boys aged 9 to 14 get two doses spaced 6 to 12 months apart. Those starting at 15 or older, or anyone immunocompromised, get three doses at 0, 1-2, and 6 months. The WHO has reviewed evidence supporting single-dose schedules, and countries like the UK and Australia now use one dose, but India currently follows the two- or three-dose standard. The vaccine works best before any exposure, which is why pre-adolescent vaccination is the global priority, though it still helps at older ages because most adults have not been exposed to every type it covers.

The vaccine is licensed in India up to age 45, and FOGSI supports catch-up vaccination for women who missed it as teenagers. The decision as an adult should weigh likely future exposure, screening history, and personal values. A 30-year-old who has never been screened and is in a new relationship is a reasonable candidate; a 45-year-old with one long-standing partner and consistently normal Pap smears may benefit less. Cost matters too, since adult vaccination is usually self-pay: Cervavac at Rs 2000 makes a three-dose series about Rs 6000, far below Gardasil 9 at roughly Rs 30,000 or more.

Vaccination does not replace screening, and this is one of the most important messages. The vaccine prevents new infection with the types it covers but does not treat existing infection or pre-cancer already present, and it covers seven to nine high-risk types, not all of them. ACOG, NICE, and FOGSI all stress the same dual strategy: vaccination plus regular cervical screening together give near-complete protection, while either alone gives only partial protection.

Safety has been studied extensively. Common side effects are local injection-site reactions (pain, swelling, redness in 50 to 80 percent), fever, headache, and fatigue, usually resolving in one to three days. Serious adverse events are very rare. Concerns raised in some media about autoimmune disease, premature ovarian insufficiency, or chronic fatigue have been investigated by WHO, EMA, the US CDC, and ICMR and have not been substantiated. The vaccine does not affect fertility or future pregnancy. The Indian Academy of Pediatrics, IMA, and FOGSI all support it unequivocally.

School-based programs achieve the highest uptake worldwide because they remove the logistical burden from families. Sikkim reached over 95 percent coverage in its school program, and similar pilots run in Punjab, Delhi, and parts of Maharashtra. National rollout under the Universal Immunization Programme has been anticipated for years and remained pending as of 2026. Meanwhile, parents can access vaccination through paediatric clinics, gynaecology practices, and hospital OPDs, ideally during a single family visit with the second dose planned six to twelve months later.

Cervical screening in India uses three main tools, each with its own cost and accuracy. The conventional Pap smear (cervical cytology) examines cells scraped from the cervix under a microscope. Liquid-based cytology (LBC) refines this and is common in tertiary centres. HPV DNA testing detects high-risk types directly and is increasingly recommended as the primary screen for women aged 30 and above. Visual Inspection with Acetic Acid (VIA), where dilute vinegar turns abnormal areas white, is a low-cost option endorsed by ICMR for community screening where lab infrastructure is limited.

Cost varies widely. A conventional Pap smear at a private lab typically costs Rs 500 to Rs 1500; LBC adds Rs 500 to Rs 1000; HPV DNA testing runs roughly Rs 2000 to Rs 4500 at chain labs like SRL, Metropolis, and Dr Lal PathLabs, depending on city and platform. VIA is essentially free through government NCD screening programs. AIIMS Delhi, JIPMER Puducherry, and PGI Chandigarh offer screening at heavily subsidised rates for referred women, and also handle Colposcopy in India: Why It's Needed, How It's Done, and What It Costs and biopsy when initial results are abnormal.

The global trend, supported by NICE and WHO, is to move toward HPV testing as the primary screen for women 30 and above, with cytology reserved for triaging HPV-positive results. The logic is simple: HPV testing is more sensitive than cytology for high-grade lesions, so a negative HPV test allows a five-year interval, whereas a negative Pap allows only three. In India this transition is gradual and more visible in tertiary care. FOGSI supports HPV-based screening for women 30 to 65 every five years, or co-testing with cytology, where infrastructure allows.

Screening recommendations by age, broadly aligned with international guidance, are: no screening before age 21 (or before sexual debut plus 3 years if earlier); cytology every 3 years from 21 to 29; HPV testing every 5 years (or co-testing every 5 years, or cytology every 3 years) from 30 to 65; and stopping after 65 if prior screening has been consistently negative. Women with HIV, transplants, or other immunosuppression need more frequent screening, often annually. Women treated for high-grade dysplasia continue screening for at least 20 years, even past 65. These rules deliberately favour consistency, because the single biggest determinant of outcome is whether screening happens at all.

VIA deserves special mention in India because it is the workhorse of community screening. A trained health worker applies 5 percent acetic acid through a speculum and inspects for acetowhite changes. It costs almost nothing, needs only a speculum, light, and trained eye, and works in primary health centres without Pap infrastructure. Its sensitivity is lower than HPV testing and its specificity lower than cytology, but in low-coverage populations an imperfect tool used widely beats a perfect tool used rarely. ICMR-NICPR has trained thousands of ANMs and ASHAs in VIA, with the Tamil Nadu and Kerala models showing meaningful early-detection gains.

Self-sampling for HPV is an emerging option for women who can't or won't have a speculum exam. You collect a vaginal sample with a swab at home and return it to a lab. Sensitivity for high-risk HPV is comparable to clinician-collected samples in studies summarised by WHO. Kits are not yet widely sold in India but are being piloted by ICMR-NICPR and some private labs. For working women in cities, those with mobility limits, or anyone who avoids clinic visits for cultural reasons, this could meaningfully widen coverage. It also pairs naturally with broader STI screening for women.

An abnormal screening result is not a cancer diagnosis, and this is the single most important message for anyone who receives one. Screening identifies women who need closer evaluation; it does not diagnose cancer by itself. The next step depends on what was found. A positive HPV test with normal cytology in a woman 30 or above usually means repeat testing in 12 months, because most of these infections will have cleared. A positive HPV 16 or 18 result, even with normal cytology, typically prompts immediate colposcopy because these two types carry the highest progression risk. For a practical walkthrough, see our guide to an abnormal Pap smear and the next steps.

Abnormal cytology is described using the Bethesda system. ASCUS (atypical squamous cells of undetermined significance) is the mildest and most common, often reflecting transient HPV or inflammation. LSIL (low-grade squamous intraepithelial lesion) corresponds roughly to CIN 1 on biopsy and usually regresses without treatment within one to two years. HSIL (high-grade) corresponds to CIN 2 or CIN 3 and needs active treatment, with CIN 3 carrying roughly a 30 percent risk of progressing to invasive cancer over 30 years if untreated. AGC (atypical glandular cells) is uncommon but important and prompts more aggressive workup including endometrial sampling. ACOG maps each result to a specific management algorithm.

Colposcopy is the procedure used to evaluate abnormal results. A speculum is placed, dilute acetic acid is applied, and a magnifying instrument identifies abnormal (white) areas; Lugol's iodine may be added to highlight them. If suspicious areas are seen, a small biopsy is taken. In India, colposcopy is widely available, with private costs typically Rs 1500 to Rs 4000 including biopsy and much less at government hospitals. It is uncomfortable but not usually painful, takes about 15 to 20 minutes, and may cause some spotting or mild cramping afterward.

If biopsy confirms CIN 2 or CIN 3, treatment is usually a Loop Electrosurgical Excision Procedure (LEEP) or, less often now, cold-knife conisation. LEEP uses a thin electrified wire to remove the abnormal area under local anaesthesia, takes 10 to 15 minutes, and most women resume normal activity within a day or two, with pelvic rest (no intercourse, tampons, or strenuous exercise) advised for four weeks. Cure rates for CIN 2/3 exceed 90 percent, though follow-up continues for at least 20 years because the underlying HPV may persist. CIN 1 is usually watched rather than treated, because regression is common and treatment carries a small risk to future fertility, particularly preterm birth.

The emotional impact is often underestimated by clinicians who handle these every day. Women frequently describe months of anxiety while waiting for follow-up, with disrupted sleep, fear of cancer, and uncertainty about talking to partners. Clear counselling at the time of the result, explaining each step and the realistic outcomes, makes a big difference. Tertiary centres like AIIMS and Tata Memorial have dedicated counsellors; in busy primary and secondary care, simply being given time to ask questions can transform the experience.

After successful LEEP, follow-up usually involves HPV testing and cytology at 6 and 12 months, then annually or co-testing every three years depending on results. High-grade dysplasia recurs in roughly 5 to 10 percent of cases, most often within the first two years, which is why early surveillance is intensive. Women planning future pregnancies should tell their obstetrician about prior LEEP at the booking visit so cervical length can be monitored in the second trimester if a significant volume was removed.

Genital warts, technically condyloma acuminata, are caused mainly by HPV types 6 and 11. These are low-risk types that do not cause cancer, but they produce visible lesions ranging from tiny flesh-coloured bumps to larger cauliflower-like growths on the vulva, vagina, cervix, anus, or perianal skin (and on the penis, scrotum, or anus in men). Warts usually appear weeks to months after exposure, though some people stay asymptomatic carriers and never develop them. They are common, with global prevalence of 1 to 5 percent in sexually active adults at any time, and Indian STI-clinic data suggest similar ranges. Our genital warts guide covers identification and care in more detail.

Importantly, having genital warts does not mean a higher cervical cancer risk. Types 6 and 11 are biologically distinct from oncogenic 16 and 18 and do not drive the same E6/E7 changes. However, women with warts may have been exposed to several types at once, so cervical screening should follow standard recommendations rather than being accelerated. Warts are also a useful prompt to consider vaccination for a partner who is still eligible.

Treatment in India typically uses topical agents (imiquimod cream, podophyllotoxin solution), cryotherapy with liquid nitrogen, electrocautery, or laser ablation for resistant lesions. Imiquimod (Imiquad, Vyloma, Aldara) costs roughly Rs 800 to Rs 2500 per tube and is self-applied three times a week for up to 16 weeks. Cryotherapy and electrocautery at clinics generally cost Rs 1500 to Rs 5000 per session, often needing several. About 30 percent of cases resolve spontaneously within four months, so watchful waiting is reasonable for small, symptom-free warts. Treatment removes visible lesions but not the underlying infection, which is why recurrence is common in the first three to six months.

Recurrence frustrates many patients but is biologically expected. The skin around the original warts retains HPV DNA, which can produce new warts as those cells cycle through replication. Recurrence is usually not treatment failure; it is the natural behaviour of the virus. With continued immune response, recurrences typically become less frequent and stop within one to two years. Persistent warts beyond this sometimes prompt biopsy to exclude high-grade dysplasia, particularly in immunosuppressed patients.

There is no role for routine partner notification for cervical HPV the way there is for syphilis or gonorrhoea, because management doesn't change. For visible warts, it is reasonable for partners to be examined and to discuss vaccination if eligible. Stigma matters here: warts feel frightening, but the condition is extremely common, treatable, and caused by types not linked to cancer. A frank conversation with a gynaecologist beats online searches that blur wart-causing and cancer-causing HPV.

In pregnancy, warts may grow faster because of increased hormones and blood flow, and they sometimes regress after delivery. Treatment options are limited because imiquimod and podophyllotoxin are avoided; cryotherapy or surgical removal is preferred if needed. Vaginal delivery is generally safe even with warts present, unless they are large enough to obstruct delivery or cause significant bleeding, which is rare. The very small risk of vertical transmission causing juvenile recurrent respiratory papillomatosis is not reliably prevented by caesarean, so delivery route is decided on standard obstetric grounds.

HPV during pregnancy is common and, in most cases, does not affect the pregnancy or delivery. Normal cervical changes in pregnancy, including increased blood supply and shifts in the transformation zone, can occasionally make screening harder to interpret, but the principles stay the same: identify high-grade lesions early, monitor low-grade changes, and avoid unnecessary intervention. Screening that falls due during pregnancy is usually continued, though colposcopy is done by experienced clinicians and biopsy is avoided unless cancer is genuinely suspected.

Cervical biopsy in pregnancy carries a small bleeding risk because of increased vascularity but is safe when clinically necessary. Treatment of CIN 2 or 3 is usually deferred until after delivery if cancer is not suspected, since lesions can be monitored safely and managed straightforwardly postpartum. LEEP or conisation during pregnancy is reserved for genuine cancer concern because of risks including bleeding, miscarriage, and preterm labour. Most pregnant women with abnormal cytology are followed with colposcopy each trimester and definitive management after delivery.

Mode of delivery is not generally changed by HPV status. Vaginal delivery is safe even with low-risk warts present, unless they are extensive enough to obstruct delivery, which is rare. Caesarean is not reliably protective against vertical transmission and is not recommended for HPV alone. Transmission to the baby is possible but uncommon, and the rare juvenile recurrent respiratory papillomatosis (from HPV 6 or 11 at birth) is not prevented by caesarean according to most evidence reviewed by ACOG and FOGSI.

Women who have had a prior LEEP or conisation may have a slightly higher risk of preterm delivery later, particularly if a large amount of tissue was removed. This is why obstetricians note prior cervical treatment at the booking visit and may use transvaginal cervical length screening in the second trimester. The absolute increase is modest (roughly 1.5 to 2 fold from a baseline of about 8 percent), and the benefit of treating high-grade dysplasia clearly outweighs it in almost all cases, but it is worth knowing if you are planning pregnancy after treatment.

Postpartum cervical screening is usually resumed at the 6-week postnatal visit if it was due during pregnancy. Women with prior abnormal cytology that was monitored typically undergo definitive colposcopy and possibly biopsy then, with treatment decisions on the same algorithms as for non-pregnant women. Breastfeeding does not limit options; LEEP can be performed while breastfeeding without affecting milk supply or infant safety.

Vaccination during pregnancy is not currently recommended, though inadvertent cases studied so far show no harm. Women who started a series and then conceived should complete the remaining doses postpartum. Those planning pregnancy may choose to finish vaccination before conception to sidestep the question, though waiting is also fine. This is worth discussing with an obstetrician or gynaecologist familiar with current FOGSI and ACOG positions.

HPV affects men too, but management differs because cervical cancer is uniquely female and there is no equivalent organised screening pathway for HPV-related cancers in men. Men can develop genital warts from HPV 6 or 11, and oncogenic types can cause anal, penile, and oropharyngeal cancers, though these are far less common than cervical cancer. Anal cancer rates are notably higher in men who have sex with men, particularly those with HIV, and anal cytology and high-resolution anoscopy exist for that group in some settings, though they are not yet standard in India.

There is no widely used HPV test for men in routine practice, which often surprises patients. The reasons are practical: HPV is harder to detect on keratinised male anatomy, its natural history in men is less well characterised, and a result would not change management because there is no analogue to LEEP for an asymptomatic positive in a man. ACOG and ASRM both note that routine HPV testing of male partners has no established role. Partners cannot be 'screened and cleared' the way some women hope, so the focus stays on each person's own surveillance and vaccination.

Male vaccination is recommended and increasingly available in India, though uptake is lower than for girls. Vaccinating boys aged 9 to 14 reduces their own risk of warts and HPV cancers and adds herd protection that benefits unvaccinated women. The cost and schedule are identical to girls (Cervavac at Rs 2000 per dose or Gardasil 9 at Rs 10,500). FOGSI and the Indian Academy of Pediatrics support gender-neutral vaccination, though school programs still focus mainly on girls; privately, paediatricians and gynaecologists vaccinate boys on parental request.

The partner conversation is often hard because of the social meaning attached to STIs. A few principles help. First, HPV is so common that within a long-term relationship both partners likely share the same strains, so 'who gave it to whom' is usually unanswerable and not clinically useful. Second, a positive result today cannot date when infection occurred and may predate the current relationship by years. Third, the goal of disclosure is mutual care and shared decisions about vaccination and screening, not blame. Couples who handle this well treat HPV as a shared health issue rather than a personal failing.

For men in same-sex relationships, particularly receptive partners, anal HPV deserves more attention than it gets in India. Anal cancer is rare but rising, and persistent high-risk HPV causes most cases. Vaccination offers meaningful protection, and where available, anal cytology for men with HIV or other high-risk profiles is reasonable. Indian guidance here is evolving; specialist STI clinics, especially those linked to HIV programs, are the most informed resource currently.

For women in same-sex relationships, HPV transmission still occurs and screening recommendations are unchanged. The myth that women who only have sex with women don't need cervical screening has caused real harm and is not supported by any evidence. HPV transmits between female partners through skin and mucous-membrane contact just as it does between any partners, and the cancer pathway is identical. FOGSI and ACOG both explicitly include sexual minorities in their cervical screening recommendations.

Cervical cancer accounts for nearly 17 percent of all cancer deaths in Indian women, making it the second leading cause after breast cancer, per ICMR-NCDIR registry data. India carries roughly a quarter of the world's cervical cancer deaths despite having under a fifth of the world's women. The reasons are well understood: low screening coverage (estimated under 10 percent of eligible women ever screened), late presentation, limited rural access to colposcopy and treatment, and persistent stigma. The age-adjusted incidence is roughly 14 per 100,000 women per year, against 6 in the US and 3 in Australia, where screening and vaccination are well established. For how this compares with other women's cancers, see our overview of cervical cancer risk factors.

The infrastructure to change this is being built. AIIMS Delhi, JIPMER Puducherry, PGI Chandigarh, and Tata Memorial Mumbai all run high-volume gynaecology-oncology services with HPV testing, colposcopy, LEEP, and surgical oncology. State cancer institutes in Bengaluru, Hyderabad, Chennai, and Kolkata provide similar services regionally, and the National Cancer Grid links over 200 centres for protocol standardisation. The challenge is less the existence of services than the path that brings women to them while treatment is still curative.

Cervavac has lowered the vaccination cost barrier meaningfully, but population-level uptake still needs school-based programs, government subsidy, or sustained out-of-pocket payment. States including Sikkim, Punjab, and Delhi have piloted school vaccination with varying integration into the Universal Immunization Programme; national rollout is anticipated but slow. Meanwhile, parents of adolescent girls and boys can access vaccination at most paediatric clinics and gynaecology practices, and some employer and private-school health programs now offer it.

Screening access is similarly mixed. Government hospitals offer free or near-free Pap smears and increasingly HPV testing, but the journey often involves long waits, multiple visits, and unfamiliar processes that deter women new to preventive care. Private screening is accessible but costs Rs 500 to Rs 4500 depending on test and lab. Mobile units and camp-based VIA programs run by groups like CAPED and the Indian Cancer Society reach underserved populations, but coverage remains far below what is needed.

Stigma slows almost every part of the pathway. Adolescent girls and parents are often uncomfortable with an STI-linked vaccine, delaying or refusing it. Adult women avoid Pap smears over discomfort, fear of a bad result, or modesty concerns about pelvic exams. Husbands and families may not support screening or may misread an HPV diagnosis as proof of infidelity. Each barrier is addressable with patient, culturally aware counselling, but together they keep screening rates an order of magnitude below what is needed.

The most important single behaviour for any individual woman is simply to get screened once, then again on schedule. That step alone prevents most cervical cancer deaths. It does not require deep knowledge of HPV biology or choosing between competing tests. A woman who has her first Pap at 30, follows up appropriately if abnormal, and continues five-yearly screening cuts her lifetime cervical cancer risk by more than 80 percent in long-term modelling, one of the highest returns on a single preventive behaviour in all of medicine. If a pelvic exam feels daunting, knowing what to expect from your first Pap smear can make the visit far less intimidating.

HPV itself usually causes no symptoms, so the most important reason to see a doctor is not a symptom at all but a schedule: book cervical screening once you reach the recommended age and keep to your interval. Beyond that, certain signs warrant a prompt appointment with a gynaecologist.

• WHO — Human papillomavirus and cervical cancer (fact sheet)
• WHO — Human papillomavirus (HPV) vaccines: position paper)
• ACOG — Human Papillomavirus (HPV) Vaccination FAQ
• ACOG — Cervical Cancer Screening
• IARC / WHO — HPV and cervical cancer (Globocan, India profile)
• ICMR-NICPR — Cervical cancer and screening guidance, India
• FOGSI — Good Clinical Practice Recommendations on Cervical Cancer Screening and HPV Vaccination
• NICE — Cervical screening (NHS guidance)